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Abstract
Background: The androgen receptor (AR) is a steroid-activated transcription factor that binds at specific DNA locations and
plays a key role in the etiology of prostate cancer. While numerous studies have identified a clear connection between AR
binding and expression of target genes for a limited number of loci, high-throughput elucidation of these sites allows for a
deeper understanding of the complexities of this process.
Methodology/Principal Findings: We have mapped 189 AR occupied regions (ARORs) and 1,388 histone H3 acetylation
(AcH3) loci to a 3% continuous stretch of human genomic DNA using chromatin immunoprecipitation (ChIP) microarray
analysis. Of 62 highly reproducible ARORs, 32 (52%) were also marked by AcH3. While the number of ARORs detected in
prostate cancer cells exceeded the number of nearby DHT-responsive genes, the AcH3 mark defined a subclass of ARORs
much more highly associated with such genes – 12% of the genes flanking AcH3+ARORs were DHT-responsive, compared
to only 1% of genes flanking AcH32ARORs. Most ARORs contained enhancer activities as detected in luciferase reporter
assays. Analysis of the AROR sequences, followed by site-directed ChIP, identified binding sites for AR transcriptional
coregulators FoxA1, CEBPb, NFI and GATA2, which had diverse effects on endogenous AR target gene expression levels in
siRNA knockout experiments.
Conclusions/Significance: We suggest that only some ARORs function under the given physiological conditions, utilizing
diverse mechanisms. This diversity points to differential regulation of gene expression by the same transcription factor
related to the chromatin structure.
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Introduction
The ‘textbook’ paradigm of gene regulation by steroid hormone
receptors entails the binding of receptors to hormone response
elements located 59-upstream of the transcription start sites (TSSs)
of responsive genes, followed by the recruitment of non-DNA-
binding coactivators or corepressors. These latter factors modify
histones and interact with the basal transcriptional machinery to
modulate transcriptional initiation [1]. This paradigm is based on,
and has been the basis for, many studies in which steroid hormone
receptor binding motifs, 59-upstream of TSSs of target genes, were
identified and characterized. Thus, DNA binding locations for
steroid receptors were found where investigators looked for them.
More recent data however have revealed that the distribution of
steroid receptor occupancy genome-wide has no preference for 59-
flanking sequences of annotated genes [2,3]. Moreover, the
distribution of such sites, including androgen receptor (AR)-
occupied regions (ARORs) on chromosomes 21 & 22 [3], is poorly
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3645correlated with gene density. For this reason, two studies that used
genomic windows around the TSSs of annotated genes may have
been limited in their capacity to assign ARORs in a genome-wide
fashion [4,5] by missing functional ARORs far away on linear
DNA. Nonetheless, it is not a trivial task to assign a priori
functionality to ARORs if they are not directly associated with
promoters of nearby genes. One potential way to better assign
functionality to transcription factor binding sites, including
ARORs, is to make use of chromatin analyses. In particular,
ARORs containing active histone modifications may function as
enhancers, modulating transcription at a distance.
Histone covalent modifications, also referred to as chromatin
epigenetics, are involved in normal somatic cell development as
well as in the progression of diseases, such as cancer [6,7]. Such
histone modifications or ‘marks’ lead to the recruitment and
subsequent docking of regulatory protein complexes that modulate
transcription. These marks provide a nuanced chromatin
‘language’ that demarcate chromatin into structural domains with
dynamic functional consequences [8]. Systematic studies of
chromatin modifications have revealed a complex landscape
including ‘punctate’ sites of modified histones (histone H3 lysine
9/14 acetylation and lysine 4 di- and trimethylation) at
transcription start sites and distal regulatory elements [9,10].
Histone H3 acetylation is an epigenetic mark that allows
prediction of functional regulatory elements [11]. The molecular
mechanisms of how chromatin remodeling modulates transcrip-
tion in the context of many diseases, including prostate cancer
(PCa), will undoubtedly have a major impact in disease
understanding and management. In the case of PCa, it is known
that the progression to the fatal stage of the disease, ablation
resistance, depends to a large degree on the activity of the AR [12–
16], a potent transcription factor (TF) that facilitates epigenetic
control of gene expression at many target loci across the entire
human genome.
With the development of high throughput methodologies such
as ChIP-chip (reviewed in [17]) and more recently ChIP-seq (e.g.
[18,19]), it has become possible to comprehensively map regions in
the genome of mammalian cells that are occupied by TFs of
interest. Often, such studies identify many regions that are
occupied without any apparent functional consequence [20,21].
To determine genomic AR binding sites and better understand
their biological significance, we mapped both AR-occupied
regions (ARORs) as well as histone H3 acetylation (AcH3) states
chromosome-wide (large parts of chromosomes 19 and 20) in the
C4-2B aggressive PCa cell line. We chose the AcH3 mark, as it is a
well-characterized marker of active enhancers and promoters
[10,22]. Of the ARORs identified, only a subset has clear
functional consequences in the PCa cell line analyzed, indicating
the existence of diverse AR functions under changing physiological
circumstances.
Results
AR-occupied regions in prostate cancer cells exceed
number of DHT-responsive genes
We performed three independent AR ChIP-chip analyses using
a genomic tiling microarray (NimbleGen Systems Inc., Madison,
WI) that covers sequences on chromosomes 19 and 20 that total
about 3% of the human genome, including the classical AR target
gene PSA/KLK3. We implemented a novel peak-calling algorithm
that allowed us to identify 189 genomic regions (about 500 bp on
average) occupied by the AR in at least two of the three
experiments, with 62 [level 1 (L1) ARORs] being reproduced in all
three, and 127 [level 2 (L2) ARORs] being reproduced in exactly
two of the three (Figure 1A). Their coordinates are provided in
Table S1, where they are numbered consecutively from A001 to
A189. The AROR peaks were generally robust in multiple
sampling experiments (see Materials and Methods). Frequently,
ARORs were classified as L2 and not L1 because of missing
probes imposed by repetitive sequences and requirements of the
NimbleGen design criteria. For instance, AROR A042 encom-
passes the well-characterized PSA/KLK3 enhancer [23–25], but
was called as an L2 AROR primarily because it partly overlaps a
repeat-masked region (Figure 1B). A043 identifies a novel AROR
at the KLK locus (Figure 1B), and four other examples, ARORs
A033, A067, A128 and A129, are displayed in Figure 1C. The
AROR calling in our ChIP-chip analysis has a very low false
positive discovery rate, which is reflected by the fact that 21/21 L1
ARORs (Figure 1E) and 6/7 L2 ARORs (Figure 1F) could be
validated by site-specific independent ChIP assays. For the four
negative control (NC) regions, two of which (NC1 and NC2)
contain canonical androgen response elements (ARE), no AR
occupancy was detected (Figure 1F). Importantly, with the
exceptions of A039 and A129 (Figure 1E), we found little evidence
of ligand-independent AR occupancy, which is in line with
previous observations at the canonical AR responsive enhancer for
the PSA gene [24,26]. These exceptions, however, may have
important implications for ligand-independent signaling of the AR
as part of the ablation-resistant phenotype in advanced prostate
tumors.
Two replicates for the AcH3 ChIP-chip experiment were
sufficient because they were highly reproducible – of 1,388 regions
identified within the two replicates, 1,189 (.90%) were in
common (Figure 1A). This high reproducibility is attributable to
the stability of this lineage-specific histone modification. Mapping
of the AcH3 peaks to the human genome show that 48% of them
overlap with TSSs (Figure 1D, insert). In contrast, very few
ARORs coincide with TSSs, indicating that AR rarely occupies
proximal promoters. In fact our ARORs, like the ER-occupied
regions (ERORs) observed in MCF7 breast cancer cells [2], were
distributed randomly with respect to distance from TSSs
(Figure 1D) and were thus mainly located in introns or intergenic
sequences (Figure 1D, insert). This distribution was very similar to
that obtained for ARORs in chromosomes 21 & 22 of LNCaP cells
(Figure S1) [3]. In terms of evolutionary conservation, both the
ARORs and ERORs were only slightly more conserved across
evolution than a set of random control sequences that exclude
repetitive sequences not represented on the tiling array (Figure S2).
Extrapolation of our chromosome 19/20 results suggests that
under similar experimental and computational stringency we
would expect in the human genome just over 2,000 ARORs that
would be classified as L1 and around 6,300 as L2. Interestingly,
these estimates well exceeded the number of DHT-responsive
genes in C4-2B cells as assessed using genome-wide gene Illumina
expression arrays (primary data presented in Table S7). Even
when responsiveness was conservatively defined using a t-test
statistical Expectation Value (E-value) cutoff of 150 (permutation-
adjusted p-value=0.003), only 552 of 46,713 transcripts (1.2%)
were identified as stimulated and 416 (0.9%) repressed by DHT at
16 hours compared to vehicle control (Figure S3 and Table S2).
When we confined the analysis to the 1,232 RefSeq transcripts
corresponding to the ChIP-chip analyzed areas of chromosomes
19/20, only 24 (1.9%) were stimulated and 19 (1.5%) repressed by
DHT at the E,5 (permutation-adjusted p-value=0.004) level
(Figure 2). Yet, of the 178 transcripts containing or adjacent to an
L1 or L2 AROR, only 16 (9.0%) were regulated by DHT (12
stimulated, 4 repressed). Quantitative RT-PCR time-course
analyses of four of these genes (KLK3, PYGB, TGM2 and SERINC3)
AR-Occupied Regions
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choice of the 16-hour time point after DHT treatment. As such, it
appears that the majority of ARORs have no nearby genes
responsive to DHT in these prostate cancer cells, begging the
question of their functionality.
Histone H3 Acetylation defines a subclass of ARORs more
highly associated with DHT-stimulated genes
AR occupancy at many regions identified in our study does not
lead to alterations in expression of nearby genes as a function of
DHT exposure. Since AcH3 is a landmark of functional enhancers
[10], we examined the AcH3 state of the ARORs to determine
their possible functionality. Critically, 52% of L1 ARORs, 27% of
L2 ARORs and 12% of L3 ARORs (ARORs detected in only 1 of
3 ChIP-chip experiments) overlapped with AcH3 peaks, which is
progressively in excess of the 6% overlap predicted for random
association (Figure 3A).
To determine whether AROR acetylation has any power to
predict DHT responsiveness of nearby genes, we compared the
frequency of stimulated, repressed, and unaffected genes at loci
that contain an acetylated AROR(s), non-acetylated AROR(s), or
no AROR at all. The results (Figure 3B) show that AcH3+ARORs
are relatively enriched for DHT-stimulated transcripts. Specifical-
ly, 12.5% of the genes flanking AcH3+ARORs were DHT-
stimulated (note that the expected maximum is less than 100%, as
we don’t necessarily expect an intergenic AROR, even if
functional, to target transcripts both upstream and downstream
from the AROR). This is highly enriched (p=1.4610
27 by Fisher
exact test) relative to AcH3- ARORs and control regions without
an AROR, for both of which only 1.1% of adjacent genes were
DHT-stimulated. There was no statistically significant relationship
between repressed genes and association with ARORs, irrespective
of their acetylation status. Conversely, 11 of 24 up-regulated genes
were adjacent to an acetylated AROR, while only 1 of 24 was
adjacent to an un-acetylated AROR (Figure 2). While these results
Figure 1. Characterization of ARORs and AcH3 regions on chromosome 19 and 20. Three replicate ChIP-chip experiments identified 738
Androgen Receptor Occupied Regions (ARORs), 62 of which were common to all three replicates (L1 ARORs) and 127 common to only two of three
(L2 ARORs), while two replicate ChIP-chip experiments identified 1,388 regions with acetylated histone H3 marks, 1,189 of which were present in both
replicates (A). Genome plots are shown for the kallikrein locus (B) and three other AROR-containing loci (C), where AR-ChIP peaks are labeled, and raw
log2 ratios [from 0 (1-fold) to 2 (4-fold)] for each replicate are shown in green (AR-ChIP) and blue (AcH3-ChIP). Panel (D) shows the genomic
positioning of the 189 L1/L2 AROR peaks and 1,189 AcH3 peaks. A cumulative distribution plot (outer) shows that the distance from annotated
transcription start sites (TSSs) is similar between ARORs, Estrogen Receptor Occupied Regions (ERORs) from [2], and randomly selected regions from
the repeat-masked tiling array, while a majority of AcH3 peaks are located at or near TSSs. All three classes (AROR, EROR, and AcH3) are excluded from
exons relative to randomly selected regions (insert). The selected ARORs were validated by independent ChIP-qPCR (E–G). C4-2B cell were incubated
in phenol red-free RPMI 1640 containing 5% CSS for 3 days and then treated with 10 nM DHT or ethanol (EtOH) vehicle for 4 h. Conventional site-
specific ChIP assays were performed with anti-AR antibody. Normal IgG was used in parallel. Twenty-one L1 ARORs (E), 7 L2 ARORs (F) and 4 negative
control (NC) (see table S4) (G) regions were examined by TaqMan qPCR. Acetylated ARORs are indicated by asterisks. A042 (F) is the PSA enhancer and
acted as a positive control. All values are presented as percentage of input.
doi:10.1371/journal.pone.0003645.g001
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PLoS ONE | www.plosone.org 3 November 2008 | Volume 3 | Issue 11 | e3645Figure 2. DHT-responsive genes in C4-2B cells. Illumina expression arrays were used to measure expression levels of 46,713 transcripts in three
replicates before and three replicates after DHT exposure in C4-2B cells, including the 1,232 RefSeq transcripts within our chromosome 19/20 genome
tiling arrays, which are shown here. The student’s t-test was used to determine statistical significance, and p-values were adjusted based on random
permutations of the full dataset. This volcano plot shows the E-value (number of transcripts at the given p-value expected by chance) plotted against
the mean fold change. 24 transcripts up-regulated at the E=5 level (permutation-adjusted p-value=0.003) and 19 transcripts down-regulated, are
shown in the upper two quadrants. Transcripts are color-coded based on whether they are adjacent to an AROR, and the up-regulated transcripts
show an elevated number adjacent to acetylated, but not un-acetylated, ARORs. The inset shows a time course of endogenous gene expression. C4-
2B cells were cultured in hormone-depleted medium for 3 days and then treated with DHT (10 nM) or ethanol vehicle for the indicated times.
Expression levels of 4 representative genes were measured by real-time RT-PCR. The data is normalized to 18S expression in log scale; Values are fold
changes over the vehicle control at each time point.
doi:10.1371/journal.pone.0003645.g002
Figure 3. Histone H3 acetylation defines a distinct subclass of ARORs. Histone H3 acetylation peaks overlap 52% of the most reproducible
L1 ARORs, but only 27% of the L2 ARORs, 12% of the L3 ARORs, and 6% of random sequences from the area covered by the chromosome 19/20 tiling
array (A). Transcripts adjacent to acetylated ARORs are significantly more likely to be up-regulated in C4-2B cells, with 12.5% of transcripts showing
up-regulation, as opposed to 1.1% of those adjacent to un-acetylated ARORs, and 1.1% of those not adjacent to any AROR; this was not the case for
repressed genes (B). While un-acetylated L1/L2 ARORs are about as likely as randomized controls to cluster on the genome as shown by the
cumulative distribution plot of inter-AROR distances (C), acetylated ARORs show significantly more genomic clustering (D).
doi:10.1371/journal.pone.0003645.g003
AR-Occupied Regions
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AROR and DHT-mediated stimulation of nearby gene(s), the
majority of genes located in close proximity to ARORs, even
acetylated ones, were unresponsive (Figure 3B).
We additionally found that acetylated ARORs (Figure 3D) were
more likely to occur in clusters than were non-acetylated ARORs
(Figure 3C) (e.g. PYGB AROR cluster in Figure 1A). This is
consistent with a transcriptional role for all the acetylated ARORs,
since enhancer elements with established functions are often
clustered to assure fidelity of transcriptional enhancement by
providing redundancy or synergy among individual elements [27].
Most ARORs contain potential enhancer activity
We suspected that in many of the ARORs in C4-2B cells, the
AR was present in complexes devoid of transcriptional trans-
activation activity. We therefore tested the DHT-mediated
enhancer activity of 61 ARORs in transient transfection reporter
assays. These 61 ARORs, encompassing all of the highly
reproducible (L1) ARORs except A059 (which is in the middle
of a simple tandem repeat), were cloned upstream of a thymidine
kinase (TK) minimal promoter/luciferase reporter and subjected to
luciferase assay in the presence or absence of DHT exposure as
described in Materials and Methods. As shown in Figure 4A, forty
of the 61 L1 ARORs (66%) displayed DHT-dependent enhancer
activity with p,0.05 (single tailed t-test). Of these, 19 ARORs
stimulated activity of the heterologous TK promoter by .5-fold.
Thus, most of the ARORs have intrinsic enhancer potential,
although in most cases this potential is either not materialized or
not detectable when the AROR is assessed in its native context
based on responsiveness of adjacent genes in C4-2B cells (Figure 2
and see Discussion). Even in the luciferase assays, where the
ARORs are tested in a relatively promiscuous environment, we
observed significant variability in enhancer activity (Figure 4A),
which was not attributable to the level of occupancy (Figure 1E).
Combinatorial regulation is a fundamental and an increasingly
central aspect of transcriptional control in higher eukaryotic cells,
and we therefore hypothesized that (i) the ARORs might be
enriched for binding sites for both AR as well as AR-coregulators,
and (ii) the presence of such sites modulated responsiveness to
Figure 4. Most ARORs have enhancer potential (transactivation activity), which is associated with several sequence motifs. Transient
transfection luciferase reporter assays were carried out in duplicate, and repeated independently at least 3 times for 61 of 62 L1 ARORs before and
after DHT exposure, and the results are displayed in a volcano plot (4A) which shows the fold change between DHT+ and DHT- luciferase levels and
the p-value significance level by the Student’s t-test. At the p,0.05 level, 19 ARORs (31%) were strongly induced, while 21 ARORs (34%) were weakly
induced. From L1 ARORs, 52 sequence motifs from Transfac and de novo motif discovery algorithms were found to be significantly enriched (see text).
We performed chi-square tests to determine those motifs (B, upper) and motif pairs (B, lower) significantly enriched in the 18 strongly induced (red
bars) vs. the 19 non-responsive (blue bars) ARORs. Four motifs were identified (C), including binding sites for FoxA1, the AR, along with two de novo
motifs with similarity to FoxA1, NFI, and Oct1.
doi:10.1371/journal.pone.0003645.g004
AR-Occupied Regions
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searched for TF binding motifs enriched in the highly reproducible
L1 ARORs compared to 6200 equivalent random size-matched
sequences from the interrogated genomic territory on chromo-
somes 19 and 20. These analyses excluded the un-cloned AROR
A059, as well as A002 that contains 14 tandem canonical AREs
and would skew the analysis. The set of 60 L1 ARORs were
investigated using both scanning and de novo motif-finding
approaches. Scanning approaches using the Cis-Elements Anno-
tation System (CEAS) website [28] to map potential binding sites
of the 550 vertebrate TF binding motifs represented in the
TRANSFAC database [29], identified five potential TF binding
sites highly over-represented within the ARORs. These were ARE
(3.6-fold enrichment, p=7.2610
212), HNF3a/FoxA1-binding
motif (1.8-fold, p=2.2610
216), NFI-binding motif (1.9-fold,
p=2.7610
29), GRE (1.5-fold, p=2.5610
212), and C/EBP (1.4
fold, p=4.3610
213) (Table S3). Nonetheless, only 10 of 60 L1
ARORs (17%) contained AREs that could be considered high
stringency (PWM log-odds.8.5), whereas 38 of 60 (63%)
contained AREs with low stringency (PWM log-odds.5.0). De
novo approaches utilizing BioProspector [30], MDscan [31] and
Weeder algorithms [32] yielded a total of 525 recurring motifs
within the 60 L1 ARORs. To collapse the many similar motifs into
similarity groups, we employed linear hierarchical clustering based
on highly overlapping motifs (see Materials and Methods). This
analysis resulted in 45 motifs (Table S3), of which three (ARE,
GRE and FoxA1) had been found by CEAS as detailed above.
We next compared the distribution of the 50 motifs from both
scanning and de novo motif-finding approaches, as well as two
alternate ARE versions from the ConSite [33], between 18
ARORs (A002 was excluded from the 19 strongly induced
ARORs, not to skew the data) most responsive to DHT in
luciferase enhancer assays with the 19 least responsive (Figure 4A).
Four motifs were significantly enriched (p,0.01, t-test) in the
strongly responsive ARORs (Figure 4B): ARE (2.2-fold), FoxA1
(1.8-fold), and two de novo motifs with consensus sequences of
TTGCTT (2.2-fold) and TTGGCAAATA (3.2-fold) (Figure 4B
and C, Figure S4). The TTGGCAAATA motif appears to
resemble overlapping binding motifs for NFI, FoxA1 and Oct-1
(Figure 4C).
Pair-wise analysis of the 50 motifs and the two alternate AREs
identified only four random pair combinations significantly
enriched in the 19 most responsive ARORs (p,0.0005)
(Figure 4B). Two of these ‘response motif-pairs’ consisted of an
ARE with either the TTGCTT (4.6-fold enrichment) or
TTGGCAAATA (4.6-fold) de novo motifs. The remaining two
did not have AREs, but instead consisted of a FoxA1-binding site
with either TTGCTT (4.6-fold) or the TTGGCAAATA (11.3-
fold) motifs (Figure 4C).
Combinatorial regulation by AR coregulators
The identification of motifs enriched in ARORs (Table S3), and
in particular in responsive ARORs (Figure 4B and C), prompted
us to investigate the role of FoxA1, C/EBP, NFI and Oct-1 in
modulating AR genomic action, as well as the role of GATA2,
which has been recently implicated in AR genomic action in
LNCaP cells [3]. We tested whether these TFs are constitutively
present at ARORs in C4-2B cells, and whether occupancy is
affected by DHT-driven AR binding as tested in Figure 1E. ChIP
assays were performed with the respective antibodies, and
occupancy was determined at the 18 L1 ARORs tested in
Figure 1E, as well as the A042 L2 AROR from the known AR
target PSA/KLK3 locus. As shown in Figure 5, occupancy at the
basal state and in response to DHT varied significantly as a
function of both the AROR and the transcription factor of
interest. For example, FoxA1 was present at almost every AROR
with occupancy in most cases increasing following treatment with
DHT. Notable exceptions included the lack of FoxA1 recruitment
to AROR A002 (which contains 14 AREs), and the inability of
DHT to enhance FoxA1 occupancy of AROR A071. NFI and C/
EBPb occupancy also varied considerably among ARORs, but
was less responsive to DHT. C/EBPa in contrast, which has been
Figure 5. Occupancies of AR-coregulators on selected ARORs.
C4-2B cells were cultured in hormone-depleted medium for 3 days and
then treated with 10 nM DHT or ethanol vehicle for 4 h. Conventional
site-specific ChIP assays were performed with indicated antibodies.
Nineteen ARORs and 2 negative control (NC) regions were examined by
qPCR. The values are presented as percentage of input.
doi:10.1371/journal.pone.0003645.g005
AR-Occupied Regions
PLoS ONE | www.plosone.org 6 November 2008 | Volume 3 | Issue 11 | e3645found at ER-occupied regions in MCF7 breast cancer cells [2],
was not detected at any of our ARORs in C4-2B prostate cancer
cells (data not shown). GATA2 occupied only acetylated ARORs
near three DHT-responsive genes; PSA (A042), PYGB (A129) and
TGM2 (A156), and Oct-1 interaction was weakly observed on
several ARORs with only one of three different antibody
preparations. Interestingly, we could not always predict occupancy
of any particular AROR by FoxA1, C/EBP, NFI and Oct-1 by the
presence or absence of consensus motifs. This finding is suggestive
of complex protein-protein interactions in the recruitment of a
given TF to a specific AROR, and further indicates that the site-
specific arrangement of TFs creates a diversity of site-specific AR-
mediated transcriptional responses. For example, A129 exhibited
relatively high NFI and GATA2 occupancy, but low to
intermediate C/EBPb and FoxA1 levels, A107 had relatively
high C/EBPb, low to intermediate NFI and FoxA1 and negligible
GATA2, whereas A140, was highly occupied by FoxA1 after
DHT treatment but had low NFI, intermediate C/EBPb and
extremely low GATA2 occupancy levels.
The C4-2B cell line was originally obtained from LNCaP cells
grown as xenografts after castration [34]. They are therefore
considered ‘androgen-independent’ although AR-mediated gene
expression is still quite responsive to androgen treatments [24]. We
compared C4-2B with LNCaP cells with respect to AR and TF
occupancies (Figure S6). The occupancy levels in the absence and
presence of DHT were similar between the two cell lines,
indicating that the AR and other TF occupancies are not
dramatically affected by the androgen-dependent status of the
cells.
Using siRNAs to knock down the levels of endogenous FoxA1,
C/EBP, NFI and GATA2, we investigated the role of each of
these transcription factors in DHT-stimulation of AR target genes.
Remarkably, DHT responsiveness varied with both the TF
investigated and amongst the five tested AR target genes [PSA/
KLK3 (near A042), KLK2 (near A043), TGM2 (near A156),
TMPRSS2 (chromosome 21) and FKBP51 (chromosome 6)]
(Figure 6) in a manner not attributable to differential occupancy
(compare Figures 5 and 6). For example, knockdown of FoxA1
decreased DHT-responsiveness of TMPRSS2 and FKBP51,
enhanced that of TGM2 and did not affect PSA and KLK2
expression. In contrast, knockdown of NFI decreased DHT-
responsiveness of PSA, KLK2 and TMPRSS2, increased that of
TGM2, and did not affect FKBP51. Knockdown of GATA2
sensitized TGM2 and FKBP51 to DHT induction. Interestingly,
knockdown of C/EBPb strongly increased basal expression of PSA
and KLK2, which may reflect modification of AR action on these
genes in the absence of added ligand [24]. We had previously
analyzed occupancy at ARORs close to PSA (A042) and TGM
(A156) (Figure 5); it is interesting to note that occupancy by
FoxA1, NFI, C/EBPb, and GATA2 were all present at the
Figure 6. Expression of AR target genes after siRNA-mediated knockdown of coregulators. C4-2B cells were transfected with siRNA
targeting AR, FoxA1, NFI, CEBPb, GATA2 or non-specific (NS) regions. Two days after transfection, cells were treated with 10 nM DHT or ethanol
vehicle for 18 h. Expression levels of five AR target genes were examined by real-time RT-PCR. Relative mRNA level was normalized by GAPDH mRNA.
Efficiency of each siRNA knockdown was measured by immunoblot with indicated antibodies (upper right).
doi:10.1371/journal.pone.0003645.g006
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exerted their actions via these sites. The diverse effects of each of
the coregulators on AR function may therefore reflect a complex
regulatory mechanism suitable for modulation of DHT respon-
siveness under different physiological conditions.
Discussion
The functional consequences of AR engagement at DNA target
sites, which normally follow androgen binding to the AR, are of
major importance in the development of the male phenotype and
in diseases such as PCa. The prostate is a well-established AR
target tissue, where it is known that 5a-reductase converts
circulating testosterone to the more potent androgen, DHT.
DHT in turn binds the AR, mediates its nuclear translocation, and
promotes prostate differentiation via specific gene expression
modulation. With respect to PCa, increased life-time exposure to
enhanced AR activity predisposes men to the disease [13]. Even
more striking, aberrant AR activity seems to be necessary and
sufficient to convert androgen-dependent prostate tumors to
ablation resistant ones; this fact has made the AR an attractive
target for PCa therapy [16,35,36]. Although non-genomic actions
of the AR have been proposed [37], its major activity is thought to
be a consequence of DNA engagement and transcriptional
regulation. Due to progress in genomic techniques measuring
engagement of TFs, the quantitative and qualitative mapping of
AR/DNA engagement profiles have become the basis of a limited
number of studies during the past year [3–5], however, the control
of such engagement and its consequences remain relatively
unexplored.
In this report, we employed ChIP-chip to map the locations of
both the AR and AcH3 onto 3% of the genome in C4-2B prostate
cancer cells. AR occupancy exhibited higher inter-experimental
variance than AcH3, but was still sufficiently reproducible to
detect 62 regions occupied in every one of three independent
experiments. Aside from their exclusion from exonic sequences,
ARORs were distributed randomly with respect to gene locations.
Of the 62 highly reproducible ARORs, 32 were also marked by
AcH3. The significance of AROR acetylation was apparent when
examining gene expression patterns of neighboring genes – 12% of
genes adjacent to AcH3+ARORs were DHT-stimulated, com-
pared to only 1% of genes adjacent to AcH3- ARORs (conversely,
46% of up-regulated transcripts were adjacent to acetylated
ARORs whereas only 4% were adjacent to an un-acetylated
AROR.) While the number of differentially regulated genes on
chromosomes 19 and 20 is small, this roughly 10-fold enrichment
in functionality of ARORs with the acetylation mark illustrates the
utility of combining ChIP studies of individual transcription factors
with epigenetic markers in the same cells.
We detected many more ARORs than DHT-responsive genes,
leaving most ARORs without any detectable function in C4-2B
cells. We can speculate that these ARORs, particularly the
acetylated ones, modulate transcription at levels undetectable in
our assay, or target microRNAs or other un-annotated transcripts.
They may even function as enhancers of genes over large linear
DNA distances or on other chromosomes [38]. Transcriptional
enhancement of other genes could have been offset by compen-
satory mechanisms of RNA destabilization, or difficult to detect
due to high basal steady state levels. Finally, it is plausible that
occupancy at some ARORs was without any transcriptional
function under the experimental conditions employed. Some of
these ARORs, in particular acetylated ARORs, could be poised
for transcriptional engagement upon arrival of a missing signal.
Others may have functions unrelated to transcription, such as
chromosome structural regulation, replication or DNA repair [21].
Still others, especially non-acetylated ARORs, may have no
function at all. Thus, we envision many (even most) ARORs are
inactive in relatively condensed chromatin at any given time and
situation with or without coregulators (Figure 7, W & X); the latter
my act as pioneers to facilitate the original recruitment of AR to
the site. Some ARORs may be poised to act because they contain
modified chromatin (AcH3) and a different complement of
coregulators (Figure 7, W & Z). Only a small number of ARORs
is actually engaged in transcriptional regulation possibly again due
to the presence of another set of coregulators (Y & Z) that may
convert poised ARORs to engaged ones. We propose that engaged
ARORs will differ in activity depending on the physiological and
temporal states of the cells. W, X, Y & Z in figure 7 represent
Figure 7. Schematic model of AROR functions. Three types of AR/
DNA engagements are envisioned. Inactive ARORs represent AR
occupying sites of relatively condensed chromatin along with
coregulators W & X; these sites may simply be reservoir of AR to be
used during dramatic changes in physiological conditions. Poised
ARORs represent AR at AcH3 modified sites ready to engage the
transcription initiation machinery, but held in check by coregulaters W
&Z .Engaged ARORs represent AR actively mediating transcriptional
control of target gene(s) by looping across varying genomic distances
perhaps assisted by coregulators Y & Z.
doi:10.1371/journal.pone.0003645.g007
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allowing for qualitative adjustment of AR signaling under different
situations.
Transcriptional enhancer activity of ARORs in a standard
luciferase assay of a minimal TK promoter demonstrated that
66% of the L1 ARORs, including many without apparent
influence on endogenous genes, had transcriptional enhancement
potential in in vitro assays. Indeed, even ARORs that had no
enhancer activity in C4-2B cells turned out to be active in other
prostate cancer cell lines (data not shown). As stated above,
whether an AROR is engaged, poised, or transcriptionally
inactive, even in a non-chromosomal context after transient
transfection, likely depends on the differential occupancy of the
AROR by trans-acting factors, which modify the transcriptional
activity of the AR. This was best exemplified by the siRNA
knockdown of specific AR coregulators that had differential effects
on different DHT-responsive genes (Figure 6). These AR
coregulators, including FoxA1, C/EBPß, NFI and GATA2, were
identified here and/or in other studies [3].
FoxA1 and C/EBPa have both been implicated previously in
estrogen receptor (ER)-mediated [2] and FoxA1 in AR-mediated
[3] gene expression. The Matusik lab further showed that FoxA
proteins were expressed in the prostate and interacted with the AR,
thus modulating its activity on some but not all promoters [39].
Although FoxA2 may play a role in prostate cancer progression to
androgen independence [40], it is not expressed in C4-2B cells (data
not shown). FoxA transcription factors may act as pioneer factors,
due to their winged-helix structures, and may bind to chromatin
predominantly at distant enhancers as an initial event to which
subsequent TF may be recruited. Their binding seems to be
dependent on histone H3K4 methylation and they likely establish
lineage-specific transcription [41]. Our data, on the other hand,
have shown that in addition to FoxA1 being attracted to certain
ARORs in the absence of hormone, at other sites FoxA1
recruitment was increased after DHT treatment indicating that
FoxA1 in PCa cells has additional AR-dependent functions.
C/EBPs (CCAAT-enhancer-binding proteins) belong to a
family of transcription factors that interact with the CCAAT
box motif, which is present in the promoters of several genes. In
LNCaP cells, C/EBPa over-expression inhibited the expression of
PSA [42], indicating that it is a possible AR negative regulator.
However, C/EBPb seems more relevant in cancer cell control in a
positive way, since it is hormonally controlled and involved in cell
proliferation, whereas C/EBPa is predominantly expressed in the
terminal differentiation phases of epithelial cells. For example, C/
EBPb appears to be a key transcription factor in cell growth, since
its depletion by RNA interference blocked the stimulation of
growth hormone [43]. In our study C/EBPb (and not C/EBPa)
was found at many ARORs.
Nuclear factor I (NFI) belongs to a family of transcription factors
that play important roles in modulating transcription of differen-
tiation-associated genes [44]. Interestingly, a two-step synergistic
model was proposed to explain the interaction and activity of
progesterone receptor and NFI [45]. Although our siRNA
knockdown experiments indicated diverse effects of NFI on gene
regulation, specific roles for NFI in AR signaling have not yet been
proposed,and we believe ourfindings arenovel and may well reveal
an important pathway in AR signaling and PCa progression.
GATA family members are able to bind to DNA at their
response elements and mediate the ‘opening’ of compacted
chromatin [46] and have been proposed to play major roles in
endocrine function and disease [47]. Furthermore, GATA2 was
previously found as an AR coregulator at AR sites on chromosome
21 and 22 [3]. However, in our study GATA2 was found only at
three AROR sites. Interestingly, all three were in the proximity of
genes that were substantially stimulated by DHT treatment (PSA,
TGM2 and PYGB), indicating that this transcriptional coregulator
might potentiate the AR-mediated transcription of these genes.
However, depending on the specific enhancer, GATA2 might
have enhancing or repressing activities on gene expression, as was
shown in the siRNA knockdown experiments.
Oct-1 was proposed as an AR collaborator [3] and was shown
to physically interact with the AR in a DNA-dependent manner
that facilitated cofactor recruitment [48,49]. However, we found
only very low levels of Oct-1 at some ARORs, indicating that the
participation of Oct-1 is limited to perhaps only very few AR
regulated regions where it may play a specialized function.
We have previously reported that at some loci (but not at others)
gene-wide histone H3 acetylation leads to efficient AR-mediated
transcription in C4-2B but not in LNCaP cells [24]. Apart from
the different kallikrein loci (Figure 1B), we did not find any other
gene-wide acetylation profiles on chromosomes 19 & 20,
indicating that the expression of kallikreins is perhaps examples
of only a few genes marked in this way. From the work presented
here it is clear that coregulators also contribute significantly to
transcriptional efficiency.
The interplay between the AR and potential coregulators is very
likely promoter/enhancer specific and dependent on the pheno-
types of the target genes as was shown in the present study. Some of
the AR coregulators may be considered pioneer factors, laying the
groundwork to allow efficient AR-mediated gene modulationas was
proposed for ER activity [2]. In such cases they may even provide
the initial site for the AR to dock at enhancers or promoters that do
not contain strong AREs; in this scenario, the AR is brought into
playviaitsinteraction withthecoregulator,withweakbindingto, or
even no contact with DNA. A complex site-specific matrix of
transcription factors may therefore exist to allow specific gene
regulation under specific physiological conditions. At this stage we
do not know the rules governing AR-mediated expression control at
different loci. As a matter of fact, there are likely dozens more
coregulators that determine AR activity across all ARORs and cell
types. Deciphering the rules of AR engagement by these
coregulators across various ARORs and under different physiolog-
ical and pathological conditions may require decades of research.
Meanwhile, measuring epigenetic marks, such as histone H3
acetylation, provides a powerful approach as a functional adjunct
to characterize ARORs. The combined mapping of TF-binding
regions and histone modifications may therefore prove a beneficial
principle to be used for the functional, genome-wide characteriza-
tion of not only AR, but also that of many other TFs.
Conclusions
Over the past several decades a general concept of TF-mediated
gene regulation has emerged. It depicts a sequence of events,
starting with TFs binding at specific regions of DNA, followed by
the covalent modification of chromatin proteins (primarily
histones) to ‘open’ chromatin, and ultimately allowing the nearby
docking of the transcription machinery. This is not necessarily
always the case and alternative insights were recently revealed by
the use of new high throughput techniques, which allow the
agnostic mapping of such regions and an unbiased appreciation of
their functions. In the current study, many AR binding sites were
not associated with nearby gene expression despite the fact that
they had intrinsic positive regulatory activity in chromatin-
independent assays. On the other hand, those that regulated the
expression of nearby genes were 10-times more likely marked by
acetylation, indicating that AR occupancy and associated histone
acetylation are both necessary requirements for positive regulatory
AR-Occupied Regions
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indicates that AR occupancy does not necessarily lead to the
recruitment of histone acetylases and subsequent nearby gene
expression. Therefore, the rate-limiting step for AR-mediated gene
expression is not occupancy per se. Silent occupied regions may act
as a reservoir of bound AR, possibly poised to mediate gene
expression as conditions change. Such conditions may include
chromatin modifications and/or the recruitment of coregulators,
since most of the AR occupied regions were also co-occupied by
other TFs, which in several cases acted as coregulators of gene
expression. We conclude that the diversity of site-specific functions
of the AR points to differential regulation of gene expression by
the same transcription factor related to chromatin structure and
the presence of coregulators.
Materials and Methods
Cell Culture and Materials
Human prostate cancer C4-2B cells, obtained from ViroMed
Laboratories (Minneapolis, MN), were maintained in RPMI 1640
supplemented with 5% (v/v) fetal bovine serum (FBS). Antibodies
were anti-AR (N20), anti-HNF-3a (H-120), anti-NFI (H-300), anti-
C/EBPb (C19), anti-GATA2 (H116), normal rabbit IgG (Santa
Cruz Biotechnology, Santa Cruz, CA), anti-Oct1 (Abcam Inc.,
Cambridge, MA) and anti-AcH3-K9/K14 (Upstate Biotechnology
Inc., Lake Placid, NY). Pre-designed SMARTpool siRNA reagents
against FoxA1, NFI, C/EBPb, GATA2 and nonspecific siRNA
were purchased from Dharmacon (Lafayette, CO). AR siRNA was
described previously [24]. TaqMan qPCR probes were obtained
from Biosearch Technologies (Novata, CA).
ChIP-chip
C4-2B cells were cultured in phenol red-free RPMI 1640
supplemented with 5% charcoal/dextrane-stripped FBS (CSS) for
3 days. After 4 h DHT (10 nM) treatment, ChIP was conducted as
described previously [23] except that no salmon sperm DNA was
used as blocking reagent. The immunoprecipitated DNA and un-
enriched input DNA were treated with RNase A and purified using
the QIAquick PCR purification kit (Qiagen, Valencia, CA). The
purified DNA was blunt-ended using T4 polymerase (New England
BioLabs, Ipswich, MA), ligated to the linkers (oJW102, 59-
GCGGTGACCCGGGAGATCTGAATTC-39, and oJW103, 59-
GAATTCAGATC-39), and amplified by ligation-mediated PCR
(LM-PCR). NimbleGen Systems (Madison, WI) labeled amplified
input DNA and ChIP DNA with Cy3 and Cy5, respectively, and
hybridized to genomic tilling arrays HG17Tilling Set 35.
Peak calling
Normalized log-ratios for each replicate were obtained from
NimbleGen and processed independently. Moving averages Mi
were determined for 600-bp windows centered on each probe i, for
all windows containing three or more probes. Statistically
significant windows were determined by comparing actual moving
average values to a null distribution obtained by permutation
sampling as follows. For each actual moving average Mi containing
j probes, we computed a null moving average M
*
i by randomly
sampling j log-ratio values from the entire dataset. This was
performed 10,000 times to generate a distribution of permuted
moving averages. A normal QQ-plot (Figure S5) indicated that
this distribution was approximately normal except for outliers in
the right tail, so we estimated mean (u ˆ) and variance (o ˆ
2)
parameters and performed a one-sided normal test to calculate
individual window p-values based on this null distribution. To
accommodate the large number of statistical tests, we used the
method of Benjamini et. al. to control the False Discovery Rate
(FDR) at an FDR (a) level of 0.005. Regions with at least four
consecutive probes were considered a peak, then peaks were
extended until the first insignificant probe was encountered, and
overlapping peaks were merged. For AcH3 occupied regions, final
peaks were those that were called in both of the replicate
experiments. For AR occupied regions (ARORs), L1 peaks were
defined as those present in all three replicate experiments, while
L2 peaks were those present in two of three.
Genomic properties of AcH3 peaks and ARORs (Fig 1D)
Distance to TSSs and genomic contexts were determined relative
to transcript annotations in the ‘‘Known Genes’’ track of the UCSC
Genome Browser. 6,200 randomized ARORs were generated by
picking random regions from chromosomes 19 and 20 with
properties matched to the actual L1 ARORs – they had the same
relative frequencies on chromosome 19 vs. 20, were matched for
size, and were required to have no more than one missing probe.
95% confidence intervals are defined as the TSS distances of the
upper 2.5% and the lower 2.5% of the randomized ARORs.
Conventional ChIP Assay
ChIP analyses on LNCaP or C4-2B cells were performed as
described previously [23]. DNA samples from ChIP preparations
were analyzed by qPCR using TaqMan PCR Master Mix
(Applied Biosystems, Branchburg, NJ). The primers and probes
are listed in Table S4.
Expression Microarray
Hormone-depleted C4-2B cells were treated with DHT (10 nM)
or an equal volume of ethanol for 16 hr. Total RNA from three
biological replicates was extracted using Aurum Total RNA Kit
(Bio-Rad, Hercules, CA) and hybridized to Human-6 v2 Expression
BeadChIP (Illumina, San Diego, CA) at the USC/Norris Cancer
Center Core Facility. To determine differentially expressed genes,
we performed a two-tailed t-test (equal variance) across three
DHT2 replicates and three DHT+ replicates for all 46,713 array
features having a valid measurement for all 6 replicates. To
determine an empirical null distribution, we generated 1,000
permutations of the data matrix by randomly shuffling the three
DHT2 and three DHT+ assignments for each array feature
(yielding roughly 47 million randomized features). An adjusted p-
value was then determined for each feature. These p-values were
converted to Expectation values (E-values) by multiplying by the
number of features (Table S2). A significance cutoff of E,=150
was chosen because it minimized the FDR (at about 0.1) and
included all well-studied AR targets in prostate cancer cells. For
AROR comparisons, we only considered the 1,232 RefSeq
transcripts covered by the chromosome 19 & 20 regions on the
NimbleGen tiling array, and set a significance cutoff of E,=5,
corresponding to the E-value chosen for the full genome, and also
occurring at the minimum achievable False Discovery Rate (FDR)
of 0.1. This cutoff also included all features with fold changes of 1.5
or greater, and included all well-studied AR targets in prostate cells.
An AROR was considered ‘‘adjacent’’ to a RefSeq feature if it was
within the annotated gene or one of its introns, or if it was upstream
or downstream of the gene with no other intervening genes.
Inter-AROR distances (Figure 3C & D)
Distances were calculated between each pair of AcH32ARORs
(3C) and each pair of AcH3+ARORs (3D). Chromosome and size-
matched randomized ARORs were generated as described above.
For each trial, we generated sets with the same number of ARORs
AR-Occupied Regions
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interval, we took the upper 2.5% and the lower 2.5% of distances
for 10,000 independent trials.
Construction of Plasmids
The AROR sequences (an average of 500 bp fragment
surrounding the AROR peak center) were PCR amplified from
C4-2B genomic DNA and subcloned upstream of a thymidine
kinase (TK) minimal promoter-luciferase vector [from Dr Axel
Scho ¨nthal (USC)] in both directions. The primers for subcloning
are listed in Table S5.
Luciferase Assay and DHT responsiveness
C4-2B (1610
5 cells/well) were plated in 12-well plates and
grown in phenol red-free RPMI 1640 containing 5% CSS for 2
days. Cells were then transfected with AROR containing TK-
luciferase reporter plasmids using Lipofectamine LTX Reagent
(Invitrogen Corp., Carlsbad, CA) according to the manufacturer’s
protocol. After transfection, cells were treated with DHT (10 nM)
or ethanol vehicle for 24 h. Luciferase activities were measured as
previously described [23]. For each construct, two independent
transformants were measured in the DHT2 condition and two in
the DHT+ condition. Log intensities were used to perform a one
sided t-test (assuming equal variance) to determine a p-value. We
used log intensities because inter-sample variance was correlated
with raw intensity scores but not with log intensity scores. The
same procedure was performed for each construct in the reverse
orientation, and the minimum of the forward and reverse p-values
was recorded. In some cases, this procedure was repeated several
times for the same construct, in which case we took the median p-
value. For Figure 4A, this p-value is plotted against the intensity
fold changes, which were averaged using the geometric mean.
Motif searches
BioProspector, MDScan, and Weeder were used to identify
motifs de novo by comparing the 60 L1 ARORs (we excluded A002
which has 14 tandem AREs, and A059 which could not be cloned)
to 6,200 size-matched controls. Each was run to search for motifs
of various lengths (6–22 for MDScan and BioProspector, 6–12 for
Weeder). The ‘‘-T 20’’ command line parameter was used for
BioProspector, and ‘‘-t 30’’ was used for MDScan. Because these
de novo search programs produce a large number of highly similar
versions of the same motif (408 for MDscan and BioProspector,
125 for Weeder), we performed a clustering technique to collapse
them to a relatively non-redundant set. We examined each
possible pair of motifs A and B, and measured the Jaccard distance
between the two motifs, which is defined as 1{
count A&B ðÞ
count AjB ðÞ , where
count(A&B) is the number of overlapping binding sites between A
and B, and count(A|B) is the total number of binding sites predicted
for either motif. Motifs were then clustered using linear
hierarchical clustering (average linkage), and motifs with an
average Jaccard distance of 0.1 or less were grouped together. The
motif with the lowest average distance to all other motifs in the
cluster was recorded as the prototype and used for all subsequent
analysis. Weeder produced 23 clusters, and BioProspector and
MDScan results were combined to yield 22. To this we added 2
versions of the ARE motif from JASPAR/ConSite, and 5 motifs
identified by CEAS (ARE, HNF3a, NFI, C/EBP, and GR) [28] to
yield a total of 52 enriched motifs (Table S3).
Motif enrichment in DHT-responsive ARORs (Figure 4B)
For each of the constructs with luciferase data, we counted the
number of predicted binding sites within the construct for each of
the 52 motifs enriched in ARORs (4B, upper), and separately
counted the number of predicted sites for each of the 1,326 unique
motif pairs (4B, lower). For each motif or motif pair, we generated
an enrichment significance score by performing a one-sided non-
parametric t-test (assuming equal variance) between the binding
site counts in the 18 strongly induced ARORs vs. the 19 non-
responsive ARORs. Adjusted p-values were determined by
randomly permuting the non-responsive and responsive labels
1,000 times for each motif, and determining an empirical
distribution of t-test scores, which was used to calibrate the actual
t-test scores.
siRNA Transfection
C4-2B (1610
5 cells/well) were plated in 6-well plates and
grown in phenol red-free RPMI 1640 containing 5% CSS for 2
days. Cells were transfected with the siRNA duplexes as indicated
at a final concentration of 100 nM using Oligofectamine Reagent
(Invitrogen) according to the manufacturer’s instructions. After
transfection, cells were grown in phenol red-free RPMI 1640
containing 5% CSS for 48 hr and then treated with DHT (10 nM)
or ethanol vehicle for additional 18 hr. Total RNA extraction and
protein extraction were conducted respectively for further
assessment.
qRT-PCR
After the indicated treatments, total RNA from C4-2B cells was
extracted using Aurum Total RNA Kit (Bio-Rad, Hercules, CA).
cDNA was prepared using iScript cDNA Synthesis Kit (Bio-Rad),
and qPCR was conducted using TaqMan PCR Master Mix or
SYBR Green PCR Master Mix (Applied Biosystems, Branchburg,
NJ). The primers and probes are listed in Table S6. Triplicate
PCR reactions were conducted. GAPDH mRNA expression was
analyzed for each sample in parallel.
Immunoblotting
Immunoblotting were performed as previously described using
the indicated antibodies [50,51].
Supporting Information
Figure S1 AROR distribution in Chromosomes 21 & 22 of
LNCaP cells. Data from Wang et al [3].
Found at: doi:10.1371/journal.pone.0003645.s001 (0.09 MB TIF)
Figure S2 Conservation of AR ChIP and AcH3 ChIP non-
coding regions. Cumulative distribution plots of 28-way phastCons
conservation scores (UCSC phastCons28way) are plotted for the
non-exonic ARORs, Estrogen Receptor Occupied Regions
(ERORs) from [2], and known enhancer elements taken from
[52]. ‘‘Random’’ ARORs are the non-exonic subset of the size-
matched randomized chromosome 19 & 20 regions described in
Figure 1D. ERORs and ARORs appear to be only slightly more
conserved than the non-coding genomic background.
Found at: doi:10.1371/journal.pone.0003645.s002 (7.99 MB TIF)
Figure S3 Hormone-dependent gene expression in C4-2B cells.
Illumina expression arrays were used to measure expression levels
of 46,713 transcripts in three replicates before and three replicates
after DHT exposure in C4-2B cells. The student’s t-test was used
to determine statistical significance, and p-values were adjusted
based on random permutations of the full dataset. This volcano
plot shows the E-value (number of transcripts at the given p-value
expected by chance) plotted against the mean fold change. 552
transcripts up-regulated at the E=150 level (permutation-adjusted
p-value=0.004), along with 416 transcripts down-regulated
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two quadrants, and of the well-studied DHT-responsive genes in
prostate cancer are labeled.
Found at: doi:10.1371/journal.pone.0003645.s003 (2.42 MB TIF)
Figure S4 Predicted ARE and coregulator binding sites in L1
ARORs. Binding sites for the ARE and 3 coregulator motifs are
shown for the AROR constructs either highly induced (upper left),
weakly induced (lower left), unchanged (upper right), and
repressed (lower right) in our luciferase reporter activity assays.
The strongly induced ARORs had a total of 70 sites in 18 ARORs
(3.9 sites per AROR), while the weakly induced had 35 sites in 21
ARORs (1.7 sites per AROR) and the unchanged had 20 sites in
19 ARORs (1.6 sites per AROR).
Found at: doi:10.1371/journal.pone.0003645.s004 (40.51 MB
TIF)
Figure S5 Normality of permuted tiling array moving averages.
Individual log-ratios from one of the AR-ChIP NimbleGen arrays
were permuted into ‘‘randomized’’ moving averages (the number
of probes per window were matched to actual 600-bp windows on
the array). 10,000 randomized moving averages were sampled and
plotted against the standard normal. The results show that they
largely follow a normal distribution. The deviating right tail comes
from enriched probes, but represent only a small fraction of all
values and do not effect the statistical testing described above
which aims to reject against the background distribution, i.e. the
bulk of moving average scores.
Found at: doi:10.1371/journal.pone.0003645.s005 (0.88 MB TIF)
Figure S6 Occupancy of AR and coregulators in LNCaP and
C4-2B cells. LNCaP and C4-2B cells were cultured in hormone-
depleted medium for 3 days and then treated with 10 nM DHT or
ethanol vehicle for 4 h. Conventional site-specific ChIP assays
were performed with indicated antibodies. The values are
presented as percentage of input.
Found at: doi:10.1371/journal.pone.0003645.s006 (3.54 MB TIF)
Figure S7 Occupancy of AR and coregulators at PSA and TGM
loci. C4-2B cells were cultured in hormone-depleted medium for 3
days and then treated with 10 nM DHT or ethanol vehicle for 4 h.
Conventional site-specific ChIP assays were performed with
indicated antibodies. PSA and TGM ARORs were re-plotted
from Figure 5. The values are presented as percentage of input.
Found at: doi:10.1371/journal.pone.0003645.s007 (51.64 MB
TIF)
Table S1 189 L1/L2 ARORs and 1,189 AcH3 occupied regions
Found at: doi:10.1371/journal.pone.0003645.s008 (0.60 MB
XLS)
Table S2 Hormone-dependent gene expression in C4-2B cells
Found at: doi:10.1371/journal.pone.0003645.s009 (4.91 MB
XLS)
Table S3 Sequence motifs enriched in ARORs
Found at: doi:10.1371/journal.pone.0003645.s010 (0.08 MB
XLS)
Table S4 ChIP-PCR, probes and primers
Found at: doi:10.1371/journal.pone.0003645.s011 (0.04 MB
XLS)
Table S5 Luciferase reporter constructs, probes and primers
Found at: doi:10.1371/journal.pone.0003645.s012 (0.03 MB
XLS)
Table S6 Quantitative PCR, probes and primers
Found at: doi:10.1371/journal.pone.0003645.s013 (0.03 MB
XLS)
Table S7 IlluminaGX.txt.gz. Illumina microarray raw expres-
sion data of C4-2B cells. Text file.
Found at: doi:10.1371/journal.pone.0003645.s014 (3.08 MB GZ)
Acknowledgements
Dr Axel Scho ¨nthal (USC) is thanked for the TK-luc plasmid and Dr. Paul
Hengen and Dr. Fengzhu Sun for helpful discussions.
Author Contributions
Conceived and designed the experiments: LJ TC GB BF GAC. Performed
the experiments: LJ UJ JPC AW GB. Analyzed the data: LJ BPB UJ XY
GB BF. Wrote the paper: BPB BF GAC. Co-directed the study: GB BF
GAC.
References
1. Rosenfeld MG, Glass CK (2001) Coregulator codes of transcriptional regulation
by nuclear receptors. J Biol Chem 276: 36865–36868.
2. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, et al. (2006) Genome-wide
analysis of estrogen receptor binding sites. Nat Genet 38: 1289–1297.
3. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, et al. (2007) A hierarchical
network of transcription factors governs androgen receptor-dependent prostate
cancer growth. Mol Cell 27: 380–392.
4. Bolton EC, So AY, Chaivorapol C, Haqq CM, Li H, et al. (2007) Cell- and
gene-specific regulation of primary target genes by the androgen receptor. Genes
Dev 21: 2005–2017.
5. Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, et al. (2007)
New androgen receptor genomic targets show an interaction with the ETS1
transcription factor. EMBO Rep.
6. Feinberg AP (2007) Phenotypic plasticity and the epigenetics of human disease.
Nature 447: 433–440.
7. Feinberg AP (2007) An epigenetic approach to cancer etiology. Cancer J 13:
70–74.
8. Berger SL (2007) The complex language of chromatin regulation during
transcription. Nature 447: 407–412.
9. Bernstein BE, Kamal M, Lindblad-Toh K, Bekiranov S, Bailey DK, et al. (2005)
Genomic maps and comparative analysis of histone modifications in human and
mouse. Cell 120: 169–181.
10. Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, et al. (2007) Distinct and
predictive chromatin signatures of transcriptional promoters and enhancers in
the human genome. Nat Genet 39: 311–318.
11. Roh TY, Cuddapah S, Zhao K (2005) Active chromatin domains are defined by
acetylation islands revealed by genome-wide mapping. Genes Dev 19: 542–552.
12. Jenster G (1999) The role of the androgen receptor in the development and
progression of prostate cancer. Semin Oncol 26: 407–421.
13. Buchanan G, Irvine RA, Coetzee GA, Tilley WD (2001) Contribution of the
androgen receptor to prostate cancer predisposition and progression. Cancer
Metastasis Rev 20: 207–223.
14. Feldman BJ, Feldman D (2001) The development of androgen-independent
prostate cancer. Nat Rev Cancer 1: 34–45.
15. Balk S (2002) Androgen receptor as a target in androgen-independent prostate
cancer. Urology 60: 132–138.
16. Debes JD, Tindall DJ (2004) Mechanisms of androgen-refractory prostate
cancer. N Engl J Med 351: 1488–1490.
17. Hudson ME, Snyder M (2006) High-throughput methods of regulatory element
discovery. Biotechniques 41: 673, 675, 677 passim.
18. Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, et al. (2007) Genome-
wide maps of chromatin state in pluripotent and lineage-committed cells. Nature
448: 553–560.
19. Robertson G, Hirst M, Bainbridge M, Bilenky M, Zhao Y, et al. (2007) Genome-
wide profiles of STAT1 DNA association using chromatin immunoprecipitation
and massively parallel sequencing. Nat Methods 4: 651–657.
20. Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, et al.
(2007) Identification and analysis of functional elements in 1% of the human
genome by the ENCODE pilot project. Nature 447: 799–816.
21. Li XY, MacArthur S, Bourgon R, Nix D, Pollard DA, et al. (2008) Transcription
factors bind thousands of active and inactive regions in the Drosophila
blastoderm. PLoS Biol 6: e27.
22. Roh TY, Ngau WC, Cui K, Landsman D, Zhao K (2004) High-resolution
genome-wide mapping of histone modifications. Nat Biotechnol 22: 1013–1016.
AR-Occupied Regions
PLoS ONE | www.plosone.org 12 November 2008 | Volume 3 | Issue 11 | e364523. Jia L, Kim J, Shen H, Clark PE, Tilley WD, et al. (2003) Androgen receptor
activity at the prostate specific antigen locus: steroidal and non-steroidal
mechanisms. Mol Cancer Res 1: 385–392.
24. Jia L, Shen HC, Wantroba M, Khalid O, Liang G, et al. (2006) Locus-wide
chromatin remodeling and enhanced androgen receptor-mediated transcription
in recurrent prostate tumor cells. Mol Cell Biol 26: 7331–7341.
25. Shang Y, Myers M, Brown M (2002) Formation of the androgen receptor
transcription complex. Mol Cell 9: 601–610.
26. Jia L, Coetzee GA (2005) Androgen Receptor-Dependent PSA Expression in
Androgen-Independent Prostate Cancer Cells Does Not Involve Androgen
Receptor Occupancy of the PSA Locus. Cancer Res 65: 8003–8008.
27. Peterson KR, Clegg CH, Navas PA, Norton EJ, Kimbrough TG, et al. (1996)
Effect of deletion of 59HS3 or 59HS2 of the human beta-globin locus control
region on the developmental regulation of globin gene expression in beta-globin
locus yeast artificial chromosome transgenic mice. Proc Natl Acad Sci U S A 93:
6605–6609.
28. Ji X, Li W, Song J, Wei L, Liu XS (2006) CEAS: cis-regulatory element
annotation system. Nucleic Acids Res 34: W551–554.
29. Wingender E, Chen X, Hehl R, Karas H, Liebich I, et al. (2000) TRANSFAC:
an integrated system for gene expression regulation. Nucleic Acids Res 28:
316–319.
30. Liu X, Brutlag DL, Liu JS (2001) BioProspector: discovering conserved DNA
motifs in upstream regulatory regions of co-expressed genes. Pac Symp
Biocomput. pp 127–138.
31. Liu XS, Brutlag DL, Liu JS (2002) An algorithm for finding protein-DNA
binding sites with applications to chromatin-immunoprecipitation microarray
experiments. Nat Biotechnol 20: 835–839.
32. Pavesi G, Mereghetti P, Mauri G, Pesole G (2004) Weeder Web: discovery of
transcription factor binding sites in a set of sequences from co-regulated genes.
Nucleic Acids Res 32: W199–203.
33. Sandelin A, Wasserman WW, Lenhard B (2004) ConSite: web-based prediction
of regulatory elements using cross-species comparison. Nucleic Acids Res 32:
W249–252.
34. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, et al. (1994)
Androgen-independent cancer progression and bone metastasis in the LNCaP
model of human prostate cancer. Cancer Res 54: 2577–2581.
35. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD (2004) Targeting the
androgen receptor: improving outcomes for castration-resistant prostate cancer.
Endocr Relat Cancer 11: 459–476.
36. Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate
cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin
Oncol 23: 8253–8261.
37. Hammes SR, Levin ER (2007) Extranuclear steroid receptors: nature and
actions. Endocr Rev 28: 726–741.
38. Nunez E, Kwon YS, Hutt KR, Hu Q, Cardamone MD, et al. (2008) Nuclear
receptor-enhanced transcription requires motor- and LSD1-dependent gene
networking in interchromatin granules. Cell 132: 996–1010.
39. Yu X, Gupta A, Wang Y, Suzuki K, Mirosevich J, et al. (2005) Foxa1 and Foxa2
interact with the androgen receptor to regulate prostate and epididymal genes
differentially. Ann N Y Acad Sci 1061: 77–93.
40. Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, et al. (2006) Expression
and role of Foxa proteins in prostate cancer. Prostate 66: 1013–1028.
41. Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, et al. (2008) FoxA1
translates epigenetic signatures into enhancer-driven lineage-specific transcrip-
tion. Cell 132: 958–970.
42. Yin H, Radomska HS, Tenen DG, Glass J (2006) Down regulation of PSA by
C/EBPalpha is associated with loss of AR expression and inhibition of PSA
promoter activity in the LNCaP cell line. BMC Cancer 6: 158.
43. Cesena TI, Cui TX, Piwien-Pilipuk G, Kaplani J, Calinescu AA, et al. (2007)
Multiple mechanisms of growth hormone-regulated gene transcription. Mol
Genet Metab 90: 126–133.
44. Jackson DA, Rowader KE, Stevens K, Jiang C, Milos P, et al. (1993) Modulation
of liver-specific transcription by interactions between hepatocyte nuclear factor 3
and nuclear factor 1 binding DNA in close apposition. Mol Cell Biol 13:
2401–2410.
45. Di Croce L, Koop R, Venditti P, Westphal HM, Nightingale KP, et al. (1999)
Two-step synergism between the progesterone receptor and the DNA-binding
domain of nuclear factor 1 on MMTV minichromosomes. Mol Cell 4: 45–54.
46. Cirillo LA, Lin FR, Cuesta I, Friedman D, Jarnik M, et al. (2002) Opening of
compacted chromatin by early developmental transcription factors HNF3
(FoxA) and GATA-4. Mol Cell 9: 279–289.
47. Viger RS, Guittot SM, Anttonen M, Wilson DB, Heikinheimo M (2008) Role of
the GATA Family of Transcription Factors in Endocrine Development,
Function, and Disease. Mol Endocrinol 22: 781–798.
48. Gonzalez MI, Robins DM (2001) Oct-1 preferentially interacts with androgen
receptor in a DNA-dependent manner that facilitates recruitment of SRC-1.
J Biol Chem 276: 6420–6428.
49. Gonzalez MI, Tovaglieri A, Robins DM (2002) Androgen receptor interactions
with Oct-1 and Brn-1 are physically and functionally distinct. Mol Cell
Endocrinol 190: 39–49.
50. Jia L, Choong CS, Ricciardelli C, Kim J, Tilley WD, et al. (2004) Androgen
receptor signaling: mechanism of interleukin-6 inhibition. Cancer Res 64:
2619–2626.
51. Kim J, Jia L, Tilley WD, Coetzee GA (2003) Dynamic methylation of histone
H3 at lysine 4 in transcriptional regulation by the androgen receptor. Nucleic
Acids Res 31: 6741–6747.
52. Elnitski L, Hardison RC, Li J, Yang S, Kolbe D, et al. (2003) Distinguishing
regulatory DNA from neutral sites. Genome Res 13: 64–72.
AR-Occupied Regions
PLoS ONE | www.plosone.org 13 November 2008 | Volume 3 | Issue 11 | e3645